Research Article
MicroRNA Expression in Cutaneous Lupus: A New Window to Understand Its Pathogenesis
Table 1
Clinical characteristics from patients with cutaneous lupus erythematosus.
| | Cutaneous lupus erythematosus | Healthy donor | value | | SCLE | DLE | | |
| | Demographics | | | | | | Age (years) | | | | | | | | | | | | Median | 34.5 | 32.5 | 45.0 | | | Range | (20-62) | (18-74) | (21-76) | | | Sex, females, (%) | 95.5 | 95 | 95 | | | Disease duration (years) | | | | | | | | | – | | | Median | 6.0 | 7.0 | | | | Range | (1-41) | (1-26) | | | | Laboratory variables | | | | | | Hemoglobin (g/dl) | | | | | | | | | | | | Median | 13.0 | 13.2 | 14.5 | | | Range | (9.3–15.8) | (11.2–16.5) | (12.5–15.8) | | | Leucocytes (cells/μl) | | | | | | | | | | | | Median | 4900 | 4900 | 5500 | | | Range | (1700–9100) | (2400–7000) | (1140–8200) | | | Lymphocytes (%) | | | | | | | | | | | | Median | 19.0 | 22.7 | 29.9 | | | Range | (8.0–33.0) | (14.9–33.5) | (18.1–47.2) | | | Monocytes (%) | | | | | | | | | | | | Median | 9.1 | 8.2 | 6.7 | | | Range | (4.4 – 15.0) | (3.0 – 13.1) | (1.0 – 10.3) | | | Neutrophils (%) | | | | | | | | | | | | Median | 72.6 | 67.6 | 62.5 | 0.003 | | Range | (53.0–82.7) | (53.6–8.8) | (43.5–73.3) | | Platelets (x103cells/μl) | | | | | | | | | | | | Median | 205.0 | 223.5 | 249.0 | | | Range | (30–360) | (128–276) | (192–306) | | | C3 (mg/dl) | | | – | | | | | | | | | Median | 68.5 | 78.7 | | | | Range | (29.4-130.4) | (28.8-132.4) | | | | C4 (mg/dl) | | | – | | | | | | | | | Median | 13.5 | 14.3 | | | | Range | (5.9-37.2) | (6.0-29.0) | | | | Anti-dsDNA (IU/ml) | | | – | | | | | | | | | Median | 49.0 | 12.5 | | | | Range | (12.3-570.0) | (7.7-1116.7) | | | | Clinical variables | | | | | | CLASI activity score | | | – | 0.01 | | | | | | | | Median | 20.0 | 12.5 | | | | Range | (9-37) | (2-29) | | | | Treatment | | | | | | Antimalarial (%) | 14 (63.6) | 13 (65) | – | | | Prednisone (mg/day) | 10 | 15 | – | | | Immunosuppressants (%) | 13 (59) | 12 (60) | – | |
|
|
